Canopy Growth (TSX:WEED) Stock Soars 6% on Strong Q3 Earnings Report

Canopy Growth (TSX:WEED)(NYSE:CGC) stock soared almost 6% after the pot company reported better-than-expected financial results.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Canopy Growth (TSX:WEED)(NYSE:CGC), the world’s largest pot producer, reported its third-quarter results on Tuesday, which beat estimates. Canopy expects to turn a profit in the second half of 2022 after aggressive cost cuts and increased demand for cannabis products helped cut losses in the third trimester. The stock rose by almost 6% following the news.

Demand for cannabis products is rising

Since the start of last year, Canopy and rivals like Aphria and Aurora Cannabis have cut expenses by shutting down plants, cutting back on indoor growing, and laying off hundreds of employees.

Canopy is also placing its hopes on the large U.S. market, which is likely to open up, thanks to the favourable opinion of the Joe Biden administration on the cannabis industry.

Market conditions have also improved. As the pandemic shut down several businesses and economies, demand for cannabis products such as gelatin bears, brownies, and drinks, known for their links to relaxation, increased.

Canopy, which sells a line of products from dried flowers to chocolates and weed-mixed drinks, said its net sales rose 23% in the quarter to $152.5 million.

Its adjusted EBITDA loss fell from $97 million to $68.4 million in the third quarter, although asset impairments and one-time restructuring costs led the company to record a loss of $829.3 million, up from $109 million in the year-ago quarter. Expenses fell 15% to $144.1 million.

Analysts polled by Bloomberg had expected Canopy to report revenue of $147.6 million and an adjusted EBITDA loss of $71.1 million.

The cannabis company says the loss was $2.43 per diluted share for the quarter ended Dec. 31, compared to a loss of $109.6 million or $0.26 per share a year earlier.

According to Canopy, its last-quarter results included $416 million in impairment charges, restructuring, and other related charges, plus $291 million resulting from non-cash changes in fair value, mainly attributable to the higher share price of the company.

Canopy announced in December that it would shut down operations at five facilities across the country and lay off more than 200 workers in a bid to cut costs.

Net revenue for what was the company’s third quarter was $152.5 million, up from $123.8 million in the same quarter a year earlier.

Cannabis net revenue totaled $98.8 million, up from $90.4 million a year earlier, driven by an increase in Canadian recreational and international medical sales. Other revenues increased to $53.7 million from $33.4 million.

Canopy Growth expects to turn a profit in 2022

Canopy expects to achieve positive adjusted EBITDA in the second half of 2022 and an adjusted EBITDA margin of 20% for the full year 2024. It also expects positive operating cash flow for all of year 2023 and positive free cash flow for the whole of 2024. Projections are based on Canopy’s cost-reduction efforts and on the forecast of a compound annual growth in net sales of 40 at 50% between 2022 and 2024.

“We are executing against our cost savings program, with several initiatives already completed and more underway to build a leaner and more agile business,” Chief Financial Officer Mike Lee said in a statement.

Shares of Canopy Growth have almost doubled in value since the start of the year. With a price-to-sales (P/S) ratio of 43.6, the stock has become expensive. It might be best to wait for a pullback before buying shares.

Should you invest $1,000 in Docebo right now?

Before you buy stock in Docebo, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Docebo wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,058.57!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 38 percentage points since 2013*.

See the Top Stocks * Returns as of 2/20/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Stephanie Bedard-Chateauneuf has no position in any of the stocks mentioned.

If You Thought Apple and Microsoft Were Big, You Need to Read This.

The steel industry produced the world's first $1 billion company in 1901, and it wasn't until 117 years later that technology giant Apple became the first-ever company to reach a $1 trillion valuation.

But what if I told you artificial intelligence (AI) is about to accelerate the pace of value creation? AI has the potential to produce several trillion-dollar companies in the future, and The Motley Fool is watching one very closely right now.

Don't fumble this potential wealth-building opportunity by navigating it alone. The Motley Fool has a proven track record of picking revolutionary growth stocks early, from Netflix to Amazon, so become a premium member today.

See the 'AI Supercycle' Stock

More on Cannabis Stocks

Medicinal research is conducted on cannabis.
Cannabis Stocks

What to Know About Canadian Cannabis Stocks for 2025

Let's dive into two top Canadian cannabis stocks and where they may be headed from here (given the recent moves…

Read more »

Researcher works in hemp field
Cannabis Stocks

Aurora Cannabis Stock Is up 46% in 2025: Are Investors Going From 5 Years of Pain to a 2025 Gain?

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good…

Read more »

A plant grows from coins.
Stocks for Beginners

3 Growth Stocks That Could Skyrocket in 2025 and Beyond

It could be a big year for these sectors, and these growth stocks in particular throughout 2025.

Read more »

money goes up and down in balance
Tech Stocks

2 TSX Stocks to Buy and 2 to Avoid in the Looming Trade War

The looming U.S.-Canada trade war has changed the business environment. Here are some TSX stocks to buy and avoid in…

Read more »

space ship model takes off
Cannabis Stocks

2 Canadian Stocks With Strong Momentum for 2025

Celestica Inc. (TSX:CLS) stock and Dollarama (TSX:DOL) stock have sustained strong price growth momentum for a long time.  Here’s why…

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Pot Stocks: Buy, Sell, or Hold in 2025?

Cannabis stocks remain a bit risky, but could long-term investors be in for more pain or far more profits?

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »